Brief: NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer
20/07/2018 04:17
July 20(Reuters) - NanoCarrier Co Ltd 4571.T
* Says NanoCarrier entered into a license and collaborative
agreement with Orient Europharma Co Ltd 4120.TWO (OEP), for
co-development of NC-6004 with a new immunotherapy combination
drug
* This clinical approach will be developed at a global level
in
regions including United States, Europe and Asian
countries(excluding Japan) for head and neck cancer patients
building upon the basic agreement dated May 15, 2018
* Under the terms of agreement, NanoCarrier grants OEP an
exclusive license to develop NC-6004 globally for head and neck
cancer, and NanoCarrier will receive a total of $8 million
clinical milestone payments
Source text in Japanese:https://goo.gl/DEJ91N
Further company coverage: 4571.T 4120.TWO
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))